FDA & FTC Updates

Verify status at the source, not in marketing copy

Regulatory status changes, and it changes in both directions — compounds move onto and off of shortage lists, approvals expand to new indications, and enforcement actions land on specific sellers. Any claim about status is only as good as its date and its link to a primary source. This library dates every regulatory statement and points to the official record; if you find an undated status claim anywhere, treat it as unverified.

Primary sources worth bookmarking

• Drugs@FDA — approval status, labeling, and approval history for a specific product.
• FDA Drug Shortages database — current shortage status, which governs some compounding pathways.
• FDA compounding pages — bulk substance lists and the 503A/503B framework.
• FDA warning letters and MedWatch — enforcement actions and adverse event reporting.
• ClinicalTrials.gov — whether a compound is genuinely in active human study, at what phase, and for what indication.
• FTC advertising guidance and enforcement releases — what health claims are lawful in marketing.
• NIH / PubMed — the underlying published literature.

What the FTC regulates that the FDA does not

• Truthfulness and substantiation of advertising claims, including social media and influencer content.
• Disclosure of material connections — paid partnerships, affiliate links, and ownership interests must be clear and conspicuous.
• Testimonials and endorsements, including the requirement that results shown be typical or clearly qualified.
• Subscription and auto-renewal disclosure practices.

How Peptide Index maintains this

• High-risk regulatory content is rechecked monthly.
• Status is updated immediately when an FDA action changes it.
• Every regulatory claim carries a date and a link to the primary record.
• Research findings and clinical availability are stated separately and never merged into a single implied endorsement.